1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Lifecome Biochemistry Co., Ltd. Class A

Lifecome Biochemistry Co., Ltd. Class A

SSZSE:002868
19.88
CNY
+0.28
(+1.43%)
-0.51EPS
3.43BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.54
2.53
3.3
3.44
2.62
2.2
1.97
2
2.37
2.14
3.29
4.17
3.34
3.27
Basic EPS, GAAP
0.28
0.27
0.67
0.79
0.6
0.48
0.37
0.28
-0.17
-0.79
-1.44
-2.86
-0.9
-0.51
Free Cash Flow per Basic Share
- -
0.33
0.75
1.03
0.54
0.22
-0.33
-1.06
-2.1
-0.95
-4.23
0.11
-1
- -
Dividend per Share
0.23
0.16
0.32
0.54
0.21
0.19
0.2
0.15
0.17
0.08
0.16
0.31
0.27
0.3
Book Value per Share
1.45
1.63
2.04
2.32
4.46
4.79
4.96
4.92
4.62
3.83
2.65
-0.17
0.41
0.46
Tangible Book Value per Share
1.38
1.56
1.92
2.2
4.37
4.58
4.75
4.65
4.35
3.63
1.4
-0.98
0.27
0.32
Basic Weighted Avg Shares
117
117
117
117
143
157
154
154
153
154
154
156
155
155
Sales/Revenue/Turnover
297
296
386
401
375
344
304
308
363
330
507
649
517
507
Operating Margin (%)
14.07
14.81
23.69
25.88
28.02
20.88
16.34
14.2
-0.2
-18.17
-25.28
-23.6
-11.77
-0.32
Depreciation Expense
- -
28
28
29
28
30
29
30
34
64
71
100
98
- -
Net Income, GAAP
33
31
78
92
86
75
57
43
-26
-122
-222
-445
-139
-79
Effective Tax Rate (%)
14.72
14.11
14.93
14.67
14.3
14.27
13.9
11.37
- -
- -
- -
- -
- -
- -
Profit Margin (%)
11.1
10.63
20.25
23
22.89
21.69
18.75
14.02
-7.17
-36.97
-43.75
-68.51
-26.96
-15.5
Working Capital
-75
-66
-34
11
445
440
449
178
-162
21
-452
-1,026
-390
-347
LT Debt
8
27
15
3
- -
- -
77
57
97
106
527
169
30
25
Total Equity
169
191
239
271
696
748
779
770
722
599
414
-25
65
72
Return on Invested Capital (%)
8.62
8.93
22.6
27.97
17.11
10.31
6.97
4.85
- -
- -
- -
- -
- -
- -
Return on Capital (%)
16.13
12.59
25.93
30.16
17.23
10.34
7.05
5.06
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
20.23
17.46
36.34
36.2
17.77
10.35
7.49
5.61
-3.51
-18.57
-44.06
- -
- -
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
330
324
294
LT Borrowings
30
45
25
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
155
155
155
Market Capitalization
5,239
5,795
3,433

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
208
243
199
Cash, Cash Equivalents & STI
56
96
51
Accounts Receivable, Net
42
57
48
Inventories
95
79
90
Total Current Liabilities
597
420
546
Payables & Accruals
- -
- -
- -
ST Debt
330
324
294
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-34.43%
-104.94%
-364.64%
Free Cash Flow
-84.58%
-152.25%
-1,047.2%
Net Income, GAAP
27.2%
64.34%
-68.7%
Sales/Revenue/Turnover
4.9%
14.01%
-20.45%
Total Cash Common Dividend
13.01%
27.29%
-12.91%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
160
166
146
177
649
2025
142
152
- -
107
517
2026
128
119
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.2
-0.36
-0.45
-1.85
-2.86
2025
-0.19
-0.19
- -
-0.36
-0.9
2026
0.04
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.09
0.03
0.13
0.31
2025
0.06
0.08
- -
0.08
0.27
2026
0.02
0.12
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jing Yang
Full Time Employees
549
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 19,Nanpu Ecological Industrial Park Nanping FU China 353400
IPO Date
May 3, 2017
Website
pclifecome.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Lifecome Biochemistry Co., Ltd. (002868.SZ) manufactures and sells biopharmaceutical products focused on animal health, including veterinary premixes, APIs, soluble powders, feed additives, food additives, and biological pesticides. Core offerings encompass bacitracin zinc products such as premix and API; colistin sulfate products including premix, API, and soluble powder; bacitracin methylene disalicylate products like premix, API, and soluble powder; probiotics such as Bacillus subtilis and Bacillus licheniformis; neomycin sulfate products; natamycin biological preservatives; and additional items like flavomycin premix and poly-γ-glutamic acid. The company, founded in 2003 and headquartered in Pucheng, Fujian Province, China, operates primarily in China with exports to over 60 countries and holds certifications including US FDA cGMP, EU-GMP, and Australia GMP. Products target livestock producers, feed mills, and food processors in the animal health and biotechnology sectors. In April 2025, the company announced plans by its controlling shareholder Shanghai Kangyi Investment Co., Ltd. and actual controller Lai Tanping to transfer shares, potentially changing control to a party engaged in cross-border logistics, prompting a trading suspension. Hangzhou Haoying Investment Partnership recently acquired a 5% stake from Hangzhou Yirui.